
Why This Drugmaker’s Tumultuous Financial Dance Might Not Be as Bad as It Seems
Axsome Therapeutics experienced a revenue surge of 43% to $385.7 million but faced a net loss of $287.2 million, reflecting a 20% drop from the previous year. Earnings per share decreased significantly to a loss of $5.99, with 98% of revenues drawn